NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
19.02
+0.37 (1.98%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NovoCure Limited
| Country | Jersey |
| Founded | 2000 |
| IPO Date | Oct 2, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,453 |
| CEO | Asaf Danziger |
Contact Details
Address: No. 4 The Forum, Grenville Street St. Helier, Y9 JE2 4UF Jersey | |
| Phone | 44 (0)15 3475 6700 |
| Website | novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Asaf Danziger | Chief Executive Officer and Director |
| William F. Doyle | Executive Chairman |
| Ashley Cordova | Chief Financial Officer |
| Wilhelmus C. M. Groenhuysen | Chief Operating Officer |
| Frank Leonard | Executive Vice President and President of Novocure Oncology |
| Prof. Yoram Palti M.D., Ph.D. | Founder and Chief Technology Officer |
| Dr. Moshe Giladi Ph.D. | Chief Science Officer |
| Ingrid Goldberg | Vice President of Investor Relations |
| Barak Ben Arye | General Counsel |
| Michael Puri | Chief Human Resources Officer |